Advances in direct oral anticoagulants in the treatment of cirrhosis-associated portal vein thrombosis / 临床肝胆病杂志
Journal of Clinical Hepatology
; (12): 199-203, 2023.
Article
de Zh
| WPRIM
| ID: wpr-960692
Bibliothèque responsable:
WPRO
ABSTRACT
Portal vein thrombosis is one of the common complications of liver cirrhosis, and anticoagulation is currently the main treatment method for this disease. Since low-molecular-weight heparin must be injected and vitamin K antagonists require regular monitoring of international normalized ratio (INR), direct oral anticoagulants have become a research hotspot in replacement therapy with the advantages of convenient oral administration, no need for INR monitoring, and high recanalization rate. This article summarizes the advances in direct oral anticoagulants in the treatment of cirrhosis-associated portal vein thrombosis, in order to lay a foundation for further clinical studies.
Texte intégral:
1
Indice:
WPRIM
langue:
Zh
Texte intégral:
Journal of Clinical Hepatology
Année:
2023
Type:
Article